{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:26:35Z","timestamp":1791584795778,"version":"4.3.4"},"reference-count":97,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Foundation","award":["120455"],"award-info":[{"award-number":["120455"]}]},{"name":"National Research Foundation","award":["129263"],"award-info":[{"award-number":["129263"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Parkinson\u2019s disease (PD), a neurodegenerative disorder, is a life-altering, debilitating disease exhibiting a severe physical, psychological, and financial burden on patients. Globally, approximately 7\u201310 million people are afflicted with this disease, with the number of cases estimated to increase to 12.9 million by 2040. PD is a progressive movement disorder with nonmotor symptoms, including insomnia, depression, anxiety, and anosmia. While current therapeutics are available to PD patients, this treatment remains palliative, necessitating alternative treatment approaches. A major hurdle in treating PD is the protective nature of the blood\u2013brain barrier (BBB) and its ability to limit access to foreign molecules, including therapeutics. Drugs utilized presently are nonspecific and administered at dosages that result in numerous adverse side effects. Nanomedicine has emerged as a potential strategy for treating many diseases. From the array of nanomaterials available, lipid nanoparticles (LNPs) possess various advantages, including enhanced permeability to the brain via passive diffusion and specific and nonspecific transporters. Their bioavailability, nontoxic nature, ability to be conjugated to drugs, and targeting moieties catapult LNPs as a promising therapeutic nanocarriers for PD. While PD-related studies are limited, their potential as therapeutics is evident in their formulations as vaccines. This review is aimed at examining the roles and properties of LNPs that make them efficient therapeutic nanodelivery vehicles for the treatment of PD, including therapeutic advances made to date.<\/jats:p>","DOI":"10.3390\/ijms23169361","type":"journal-article","created":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T22:23:13Z","timestamp":1661120593000},"page":"9361","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Lipid Nanoparticles: Promising Treatment Approach for Parkinson\u2019s Disease"],"prefix":"10.3390","volume":"23","author":[{"given":"Keelan","family":"Jagaran","sequence":"first","affiliation":[{"name":"Nano-Gene and Drug Delivery Laboratory, Discipline of Biochemistry, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-6567","authenticated-orcid":false,"given":"Moganavelli","family":"Singh","sequence":"additional","affiliation":[{"name":"Nano-Gene and Drug Delivery Laboratory, Discipline of Biochemistry, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"ref_1","unstructured":"Parkinson\u2019s News Today (2021, December 08). Parkinson\u2019s Disease Statistics. Available online: https:\/\/parkinsonsnewstoday.com\/parkinsons-disease-statistics."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","article-title":"The Parkinson pandemic\u2014A call to action","volume":"75","author":"Dorsey","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/mds.27616","article-title":"Predicting diagnosis of Parkinson\u2019s disease: A risk algorithm based on primary care presentations","volume":"34","author":"Schrag","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/jnnp-2015-311890","article-title":"The prediagnostic phase of Parkinson\u2019s disease","volume":"87","author":"Noyce","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.mcp.2016.11.001","article-title":"Genetics of Parkinson\u2019s disease","volume":"30","author":"Lill","year":"2016","journal-title":"Mol. Cell. Probes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2011.03.005","article-title":"Gene-environment interactions: Key to unraveling the mystery of Parkinson\u2019s disease","volume":"94","author":"Gao","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","article-title":"The genetic architecture of Parkinson\u2019s disease","volume":"19","author":"Blauwendraat","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Habib, S., and Singh, M. (2022). Angiopep-2-modified nanoparticles for brain-directed delivery of therapeutics: A review. Polymers, 14.","DOI":"10.3390\/polym14040712"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/2045125312470130","article-title":"Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson\u2019s disease: A review","volume":"3","author":"Poletti","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fnins.2018.00612","article-title":"Parkinson\u2019s disease: Biomarkers, treatment, and risk factors","volume":"12","author":"Emamzadeh","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.22270\/jddt.v9i6-s.3783","article-title":"Solid lipid nanoparticles for brain targeting","volume":"9","author":"Hangargekar","year":"2019","journal-title":"J. Drug Deliv. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/nnm-2018-0436","article-title":"Nutlin-loaded magnetic solid lipid nanoparticles for targeted glioblastoma treatment","volume":"14","author":"Grillone","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1124\/dmd.112.044925","article-title":"Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: Contribution of reduced clearance","volume":"40","author":"Kadam","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1176\/jnp.14.2.223","article-title":"An essay on the shaking palsy","volume":"14","author":"Parkinson","year":"2002","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s41593-018-0221-2","article-title":"Selective vulnerability in neurodegenerative diseases","volume":"21","author":"Fu","year":"2018","journal-title":"Nat. Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson disease epidemiology, pathology, genetics, and pathophysiology","volume":"36","author":"Simon","year":"2019","journal-title":"Clin. Geriatr. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","article-title":"Neuropathology of Parkinson disease","volume":"46","author":"Dickson","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00401-016-1542-4","article-title":"Proaggregant nuclear factor(s) trigger rapid formation of \u03b1-synuclein aggregates in apoptotic neurons","volume":"132","author":"Jiang","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/JPD-130230","article-title":"The role of oxidative stress in Parkinson\u2019s disease","volume":"3","author":"Dias","year":"2013","journal-title":"J. Parkinsons Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/mds.23732","article-title":"Etiology and pathogenesis of Parkinson\u2019s disease","volume":"26","author":"Schapira","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.3233\/JAD-2010-100363","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease","volume":"20","author":"Zhu","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Soreq, L., Bergman, H., Israel, Z., and Soreq, H. (2013). Deep brain stimulation modulates nonsense-mediated RNA decay in Parkinson\u2019s patients\u2019 leukocytes. BMC Genomics, 14.","DOI":"10.1186\/1471-2164-14-478"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.25441","article-title":"Concordance for Parkinson\u2019s disease in twins: A 20-year update","volume":"85","author":"Goldman","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3233\/JPD-181493","article-title":"The search for environmental causes of Parkinson\u2019s disease: Moving forward","volume":"8","author":"Chen","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/j.jalz.2014.04.014","article-title":"The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk","volume":"10","author":"Tanner","year":"2014","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-pharmtox-011613-135937","article-title":"Environmental toxins and Parkinson\u2019s disease","volume":"54","author":"Goldman","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17296","DOI":"10.1073\/pnas.1922184117","article-title":"Dopaminergic neurodegeneration induced by Parkinson\u2019s disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity","volume":"117","author":"Nguyen","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/B978-0-12-385883-2.00005-9","article-title":"Biology of mitochondria in neurodegenerative diseases","volume":"107","author":"Martin","year":"2012","journal-title":"Prog. Mol. Biol. Translat. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e29985","DOI":"10.7554\/eLife.29985","article-title":"Structure of PINK1 and mechanisms of Parkinson\u2019s disease-associated mutations","volume":"6","author":"Kumar","year":"2017","journal-title":"eLife"},{"key":"ref_31","first-page":"2117","article-title":"Diagnostic delay in Parkinson\u2019s disease caused by PRKN mutations","volume":"63","author":"Freitas","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1093\/hmg\/ddaa183","article-title":"The mechanistic role of alpha-synuclein in the nucleus: Impaired nuclear function caused by familial Parkinson\u2019s disease SNCA mutations","volume":"29","author":"Chen","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Jagaran, K., and Singh, M. (2021). Nanomedicine for neurodegenerative disorders: Focus on Alzheimer\u2019s and Parkinson\u2019s diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22169082"},{"key":"ref_34","first-page":"5755","article-title":"Current limitations in the treatment of Parkinson\u2019s and Alzheimer\u2019s diseases: State-of-the-art and future perspective of polymeric carriers","volume":"25","author":"Chiara","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.2217\/nnm-2017-0228","article-title":"An in vitro assessment of Chitosan\/Bimetallic PtAu nanocomposites as delivery vehicles for doxorubicin","volume":"12","author":"Maney","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1515\/bnm-2015-0030","article-title":"Smart multifunctional nanoparticles in nanomedicine","volume":"17","author":"Seleci","year":"2016","journal-title":"BioNanoMaterials"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13643-018-0823-5","article-title":"Nanomedicine for drug delivery in South Africa: A protocol for systematic review","volume":"7","author":"Saidi","year":"2018","journal-title":"Syst. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2217\/nnm-2021-0044","article-title":"Nanomedicine-mediated optimization of immuno-therapeutic approaches in cervical cancer","volume":"16","author":"Venkatas","year":"2021","journal-title":"Nanomedicine"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Bhatia, S. (2016). Natural Polymer Drug Delivery Systems: Nanoparticles, Plants, and Algae, Springer.","DOI":"10.1007\/978-3-319-41129-3"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijbiomac.2019.08.235","article-title":"Bio-inspired synthesis of chitosan\/copper oxide nanocomposite using rutin and their anti-proliferative activity in human lung cancer cells","volume":"141","author":"Bharathi","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2174\/1573413716666201207141657","article-title":"Selenium nanoparticles in folate-targeted delivery of the pCMV-Luc DNA reporter gene","volume":"17","author":"Maiyo","year":"2021","journal-title":"Curr. Nanosci."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Mbatha, L.S., Maiyo, F., Daniels, A., and Singh, M. (2021). Dendrimer-coated gold nanoparticles for efficient folate-targeted mRNA delivery in vitro. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060900"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2217\/nnm-2018-0462","article-title":"Sterically stabilized siRNA: Gold nanocomplexes enhance c-MYC silencing in a breast cancer cell model","volume":"14","author":"Daniels","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","article-title":"Transport of drugs across the blood\u2013brain barrier by nanoparticles","volume":"2","author":"Wohlfart","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_45","unstructured":"Venkatas, J., and Singh, M. (Curr. Cancer Drug Targets, 2022). Localized nano-mediated interleukin-12 gene therapy: Promising candidate for cancer immunotherapeutics, Curr. Cancer Drug Targets, in press."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Virlan, M.J., Miricescu, D., Radulescu, R., Sabliov, C.M., Totan, A., Calenic, B., and Greabu, M. (2016). Organic nanomaterials and their applications in the treatment of oral diseases. Molecules, 9.","DOI":"10.3390\/molecules21020207"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Habib, S., and Singh, M. (Pharm. Nanotechnol., 2022). Carbon-based Nanomaterials for delivery of small RNA molecules: A focus on potential cancer treatment applications, Pharm. Nanotechnol., in press.","DOI":"10.2174\/2211738510666220606102906"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"100104","DOI":"10.1016\/j.medidd.2021.100104","article-title":"Liposomes and mRNA: Two technologies together create a COVID-19 vaccine","volume":"12","author":"Gregoriadis","year":"2021","journal-title":"Med. Drug Discov."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Aldosari, B.N., Alfagih, I.M., and ALmurshedi, A.S. (2021). Lipid nanoparticles as delivery systems forRNA-based vaccines. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020206"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"770","DOI":"10.12688\/f1000research.25142.1","article-title":"Anti-c-MYC cholesterol based lipoplexes as onco-nanotherapeutic agents in vitro","volume":"9","author":"Habib","year":"2020","journal-title":"F1000Research"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.2147\/IJN.S59536","article-title":"Biological augmentation of rotator cuff repair using bFGF-loaded electrospun poly(lactide-co-glycolide) fibrous membranes","volume":"14","author":"Zhao","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles\u2014From liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Habib, S., Ariatti, M., and Singh, M. (2020). Anti-c-myc RNAi-based onconanotherapeutics. Biomedicines, 8.","DOI":"10.3390\/biomedicines8120612"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: Non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fimmu.2018.00155","article-title":"The multirole of liposomes in therapy and prevention of infectious diseases","volume":"9","author":"Nisini","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/ejlt.201500590","article-title":"Active targeting of asiaglycoprotein receptor using sterically stabilized lipoplexes","volume":"118","author":"Naicker","year":"2016","journal-title":"Eur. J. Lipid Sci. Technol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"326497","DOI":"10.1155\/2011\/326497","article-title":"Liposomes for use in gene delivery","volume":"2011","author":"Balazs","year":"2011","journal-title":"J. Drug Deliv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/13543776.2020.1720649","article-title":"Solid lipid nanoparticles: A review on recent perspectives and patents","volume":"30","author":"Paliwal","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Haider, M., Abdin, S.M., Kamal, L., and Orive, G. (2020). Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030288"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Habib, S., and Singh, M. (2021). Recent advances in lipid-based nanosystems for gemcitabine and gemcitabine\u2013combination therapy. Nanomaterials, 11.","DOI":"10.3390\/nano11030597"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/10667857.2018.1475142","article-title":"Preparation and characterization of artemether loaded solid lipid nanoparticles: A 32 factorial design approach","volume":"35","author":"Patil","year":"2020","journal-title":"Mater. Technol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ddtec.2016.09.003","article-title":"Glutathione conjugation dose-dependently increases brain-specific liposomal drug delivery in vitro and in vivo","volume":"20","author":"Maussang","year":"2016","journal-title":"Drug Discov. Today Technol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"320941","DOI":"10.1155\/2015\/320941","article-title":"Blood brain barrier: A challenge for effectual therapy of brain tumors","volume":"2015","author":"Bhowmik","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2217\/nnm.16.15","article-title":"Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis","volume":"11","author":"Posadas","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","article-title":"Progress and perspectives on targeting nanoparticles for brain drug delivery","volume":"6","author":"Gao","year":"2016","journal-title":"Acta Pharm. Sin."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood-brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2015.11.032","article-title":"Revisiting nanoparticle technology for blood-brain barrier transport: Unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes","volume":"222","author":"Johnsen","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2017.05.019","article-title":"Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer\u2019s disease","volume":"260","author":"Agrawal","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.2147\/IJN.S117210","article-title":"Getting into the brain: Liposome-based strategies for effective drug delivery across the blood-brain barrier","volume":"11","author":"Vieira","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1021\/acs.molpharmaceut.8b00870","article-title":"Transferrin receptor-mediated uptake at the blood-brain barrier is not impaired by Alzheimer\u2019s disease neuropathology","volume":"16","author":"Bourassa","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1021\/acsnano.2c02347","article-title":"Surface modification of lipid-based nanoparticles","volume":"16","author":"Xu","year":"2022","journal-title":"ACS Nano"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1038\/s41598-017-06888-4","article-title":"Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433)","volume":"7","author":"Kumari","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s12035-015-9672-6","article-title":"Glucose transporters at the blood-brain barrier: Function, regulation and gateways for drug delivery","volume":"54","author":"Patching","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.brainresrev.2010.05.003","article-title":"Looking at the blood-brain barrier: Molecular anatomy and possible investigation approaches","volume":"64","author":"Cardoso","year":"2010","journal-title":"Brain Res. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Gaillard, P.J., Appeldoorn, C.C., Dorland, R., Van Kregten, R., Manca, F., Vugts, D.J., Windhorst, B., van Dongen, G.A., de Vries, H.E., and Maussang, D. (2014). Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0082331"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Hoyos-Ceballos, G.P., Ruozi, B., Ottonelli, I., Da Ros, F., Vandelli, M.A., Forni, F., Daini, E., Vilella, A., Zoli, M., and Tosi, G. (2020). PLGA-PEG-ANG-2 nanoparticles for blood\u2013brain barrier crossing: Proof-of-concept study. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010072"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"20326","DOI":"10.1021\/acsami.8b04613","article-title":"Brain targeting delivery facilitated by ligand-functionalized layered double hydroxide nanoparticles","volume":"10","author":"Chen","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpharm.2014.08.020","article-title":"Angiopep-2 and activatable cell penetrating peptide dual modified nanoparticles for enhanced tumor targeting and penetrating","volume":"474","author":"Mei","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a brain-penetrating peptide\u2013drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.biomaterials.2014.10.007","article-title":"Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles","volume":"37","author":"Ruan","year":"2015","journal-title":"Biomaterials"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3390\/met5020934","article-title":"Nanotoxicology of metal oxide nanoparticles","volume":"5","author":"Seabra","year":"2015","journal-title":"Metals"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6176610","DOI":"10.1155\/2022\/6176610","article-title":"Emerging roles of green synthesized chalcogen and chalcogenide nanoparticles in cancer theranostics","volume":"2022","author":"Olawale","year":"2022","journal-title":"J. Nanotechnol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: Classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fimmu.2017.00069","article-title":"Advanced strategies in immune modulation of cancer using lipid-based nanoparticles","volume":"8","author":"Mizrahy","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1039\/C6BM00898D","article-title":"Targeting peptide functionalized liposomes towards aminopeptidase N for precise tumor diagnosis and therapy","volume":"5","author":"Jia","year":"2017","journal-title":"Biomater. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"66889","DOI":"10.18632\/oncotarget.17976","article-title":"Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment","volume":"8","author":"Belhadj","year":"2017","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.fjps.2018.04.001","article-title":"Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs","volume":"4","author":"Poovi","year":"2018","journal-title":"Future J. Pharm. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1002\/jbm.a.36141","article-title":"Tailoring of physicochemical properties of nanocarriers for effective anti-cancer applications","volume":"105","author":"Chakraborty","year":"2017","journal-title":"J. Biomed. Mater. Res. A"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jsps.2011.04.001","article-title":"Nanoparticles: Emerging carriers for drug delivery","volume":"19","author":"Mudshinge","year":"2011","journal-title":"Saudi Pharm. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"15185","DOI":"10.1038\/s41598-021-94175-8","article-title":"Dopamine-loaded nanoparticle systems circumvent the blood\u2013brain barrier restoring motor function in mouse model for Parkinson\u2019s Disease","volume":"11","author":"Lima","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Dudhipala, N., and Gorre, T. (2020). Neuroprotective effect of ropinirole lipid nanoparticles enriched hydrogel for Parkinson\u2019s disease: In vitro, ex vivo, pharmacokinetic and pharmacodynamic evaluation. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12050448"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jconrel.2018.03.019","article-title":"A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson\u2019s disease","volume":"277","author":"Qu","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Silva, S., Almeida, A.J., and Vale, N. (2021). Importance of nanoparticles for the delivery of antiparkinsonian drugs. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13040508"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A review of Patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol. Ther."},{"key":"ref_96","unstructured":"(2022, July 27). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=Parkinson+Disease&term=liposomes."},{"key":"ref_97","unstructured":"(2022, July 27). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?recrs=&cond=Parkinson+Disease&term=nanoparticles."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/16\/9361\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:12:22Z","timestamp":1760141542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/16\/9361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":97,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ijms23169361"],"URL":"https:\/\/doi.org\/10.3390\/ijms23169361","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]}}}